APRIL 21-23, 2020

BOSTON, MA USA

Emeran Mayer, World-Renowned Gastroenterologist and Neuroscientist, to Deliver Keynote Address at 4th Annual Translational Microbiome Conference

MINNEAPOLIS, November 16, 2017– Dr. Emeran Mayer will deliver the keynote address at the 4th Annual Translational Microbiome Conference. Dr Mayer is a pioneer in researching brain-body interactions, focusing especially on brain-gut interactions in relation to health and disease. Besides being a widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis. Dr. Mayer’s keynote speech is closed to the public but open to registered conference attendees. The conference, which will be hosted by Arrowhead Publishers April 18-20 at the Boston Marriott Long Wharf, provides insight and collaboration opportunities between scientists at the forefront of microbiome research and pioneering companies investing to apply microbiome-based findings to innovate medical solutions.

“Not only is Dr. Mayer a leader in microbiome research,” said John Waslif, Managing Director of Arrowhead Publishers. “His career of investigative research has uncovered such pivotal findings that entire bodies of work are growing from that rich foundation. We are fortunate to hear firsthand about his newest research in April.”

A prolific research author, Dr. Mayer has published 210 original manuscripts in leading GI and Neuroscience journals, and 95 book chapters and reviews, has co-edited three books, and serves as Associate Editor of Gastroenterology. He is director of the Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress. Having served as president of the Functional Brain Gut group, he is also a regular member of the National Institute of Diabetes and Digestive and Kidney Diseases’ Clinical, Integrative and Molecular Gastroenterology study section. Dr. Mayer is currently engaged in research on sex differences in functional GI disorders, brain-bladder interactions, and brain imaging in IBS.

Just as Dr. Mayer’s findings span several medical specialties, his and other recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, and scientists are discovering specific variables within the microbiome that can profoundly impact a variety of conditions and diseases. To align with these findings and support exploration of translational applications, conference topics are broadly applicable, spanning multiple disease states, including oncology and dermatology, as well as inflammatory, cognitive and digestive disorders. In addition to Dr. Mayer’s keynote, progress from other groundbreaking researchers will be shared in conference sessions, and poster board presentations will offer direct access to discuss recent findings and current studies of key interest to the microbiome discussion.

The Translational Microbiome Conference will focus and build upon the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. Research in the microbiome represents tremendous potential to provide more effective therapies and supplements, and as investment opportunities are growing in this area, many companies are rapidly pursuing potential translational work. Sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings, and sessions will offer insight to how innovative companies are meeting challenges head-on to apply recent discoveries to a variety of disease processes.

Additional speakers for the 2018 Translational Microbiome Conference will be announced soon, and further information about the conference can be found at www.microbiomeconference.com.

Continuing Medical Education Credits Now Available for this Event

Joint-Providership Accreditation and Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Office of Continuing Medical Education of the University of Virginia School of Medicine and Arrowhead Publishers. The Office of Continuing Medical Education of the University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians

The University of Virginia School of Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity. (The number of credits offered for this event is subject to change dependent upon future additions/revisions to the agenda.)

The University of Virginia School of Medicine, as accredited provider, awards 8 hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)TM ) to a participant who successfully completes this educational activity. The University of Virginia School of Medicine maintains a record of participation for six (6) years.

Shahram Lavasani, Ph.D.

Founder, Chief Executive Officer and Chief Scientific Officer
Immune Biotech

Profile coming soon.

Scott Jackson, Ph.D.

Group Leader, Complex Microbial Systems
NIST (National Institute of Standards & Technology

Profile coming soon.

Rachel Clemens, Ph.D.

Commerical Innovation Manager, Life Science Lead
ISS US National Lab, Center for Advancement in Science in Space

Profile coming soon.

Lynne Elmore, Ph.D.

Director, Translational Cancer Research Program
American Cancer Society

Lynne Elmore, PhD, is the director of the Translational Cancer Research program in the Extramural Grants department of the American Cancer Society (ACS). She manages a research portfolio focused on cell biology, infectious disease, the microbiome, molecular genetics, and cancer drug discovery.

Garth Ehrlich, Ph.D.

Professor of Microbiology & Immunology, Professor of Otolayngology - Head & Neck Surgery
Drexel University College of Medicine

Dr Ehrlich is Professor of Microbiology and Immunology, and Otolaryngology-Head and Neck Surgery at Drexel University College of Medicine (DUCOM) in Philadelphia, PA, USA. Dr. Ehrlich is also the founder and director of three Research Centers of Excellence in the Institute for Molecular Medicine and Infectious Disease: the Center for Genomic Sciences (CGS); the Center for Advanced Microbial Processing (CAMP); and the Center for Surgical Infections and Biofilms.

He also directs Drexel University’s Core Genomics Facility and the Meta-Omics Shared Resource for the Sidney Kimmel Cancer Center – an NCI-designated Cancer Center.

Momo Vuyisich, Ph.D.

Chief Scientific Officer
Viome

Momo Vuyisich is a co-founder and Chief Science Officer at Viome, a data-driven personalized nutrition company. Momo provides scientific leadership at Viome and his vision is to revolutionize healthcare from "symptoms management" to a true preventative medicine. He leads product development, clinical test implementation, and comprehensive clinical research portfolio.

Momo is also an Adjunct Professor at the University of New Mexico and New Mexico Tech. Before co-founding Viome in 2016, Momo spent 12 years at Los Alamos National Laboratory, where he led the Applied Genomics team, which developed the core technology used by Viome today.

Nancy Caralla

Founding President, Executive Director
C Diff Foundation

Nancy C Caralla is a three-time Clostridioides difficile infection (CDI) survivor. She has accumulated over 25 years of experience in the nursing profession blended with over 30 years in international construction management. Over the past several years, Nancy, in partnership with C Diff Foundation members, has focused on raising C. difficile awareness through education and advocating for Clostridium difficile infection prevention, treatments, clinical trials, AMR, and environmental safety worldwide. The C Diff Foundation is a non-profit organization that takes great pride in its volunteers, chairpersons, and committees.

Rachel Teitelbaum, Ph.D.

Chief Executive Officer
Hervana

Profile coming soon.

Sonia Timerlake, Ph.D.

Vice President of Research
Finch Therapeutics

Dr. Sonia Timberlake is the VP of Research at Finch Therapeutics, a microbiome therapeutics company. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.

Dae-Wook Kang, Ph.D.

Assistant Professor, Department of Civil & Environmental Engineering
University of Toledo

Profile coming soon.

Sameer Sonkusale, Ph.D.

Prof. of Electrical & Computer Engineering, Prof. of Biomedical Engineering (adjunct), Director/Principal Investigator, Nano Lab
Tufts University

Profile coming soon.

Amy Feehan, Ph.D.

Research Scientist
Ochsner Health System

Dr. Feehan is an early stage investigator who received her BS and PhD in Neuroscience from The Brain Institute at Tulane University in New Orleans. She has conducted research in humans and rodents covering topics ranging from drug development of novel endomorphin analogs for pain, to sleep and circadian rhythms research and most recently the gut-brain axis and infectious disease. Her doctoral work led to two patents for a compound that reverses both acute and chronic pain with no observable risk of addiction. She currently works as a research scientist in the Infectious Disease department at Ochsner in New Orleans designing and executing investigator-initiated clinical trials.